Kalium chloride solution for i/v infusion

Country: Armenia

Language: English

Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Active ingredient:

potassium chloride

Available from:

Liqvor CJSC

ATC code:

A12BA01

INN (International Name):

potassium chloride

Dosage:

40mg/ml

Pharmaceutical form:

solution for i/v infusion

Units in package:

200ml plastic pack

Prescription type:

Prescription

Authorization status:

Registered

Authorization date:

2016-06-08

Patient Information leaflet

1 INSTRUCTION
ON THE DRUG MEDICAL USE
KALIUM CHLORIDE
solution for infusion 4 %
REGISTRATION NUMBER:
COMMERCIAL TITLE:
Kalium Chloride
INTERNATIONAL NONPROPRIETARY NAME:
Potassium chloride
DOSAGE FORM:
Solution for infusion 4 %
COMPOSITION: _Active ingredient_
: potassium chloride – 4,0 g,
_inactive ingredient_
: water for
injection – up to 100 ml.
DESCRIPTION:
Clear, colorless solution.
PHARMACOTHERAPEUTICAL GROUP –
Potassium preparations
CODE ATC:
В05XА01
PHARMACOLOGICAL EFFECT
_PHARMACODYNAMICS_
Potassium is the major ion of body cells, plays an important role in
the regulation of various
body functions.
It is essential for maintenance of acid-base balance, isotonicity and
electric
membrane potential of cell.
It is necessary for the conduction of nerve impulses and muscular
contraction. The drug
improves muscular contraction in muscular dystrophy and myasthenia.
Potassium chloride is used as a source of potassium ions for prevent
and recovery potassium
deficiency in body.
_PHARMACOKINETICS _
Potassium chloride is vell and quickly absorbed through the
gastrointestinal tract; mainly
excreted by the kidneys by secretion in the distal tubule, where also
is exchange sodium-
potassium ions.
The ability of the kidneys to maintain potassium is insignificant, its
urinary excretion is
maintained even in significant decrease of potassium level in the
body.
Tubular secretion of potassium is influenced by chloride ion
concentration, hydrogen ion
exchange, acid-base balance, and adrenal hormones.
A small amount of potassium excreted in faeces, and saliva, then with
bile and pancreatic juice.
2
INDICATIONS
Prevention and treatment of hypokalemia, caused by various reasons
(use saluretics, increased
potassium
excretion
by
the
kidneys,
etc.);
prevention
of
hypokalemia
in
patients
with
arrhythmias or patients taking digitalis preparations; intoxication
with digitalis drugs.
DOSAGE AND ADMINISTRATION
_THE DRUG IS USED ONLY IN DILUTED FORM. _
Adults, children and elderly intravenously by infusion (20 - 30 drops
per minute

Summary of Product characteristics

CYMMA
PI{Afl
,YAPA
KTEPHCTHI{A
JI
E
K.{PCTB
E
H
HO
TO
NF
E
N
A PATA
(fiPC)
KAJIltg
xJroPHA
pacrBop
Arrn
HH(l}y3Hrl
4
%
1.
Konrmepqec*oe
Har{MeHoBaHHe
nperaparor:
I(AJI!{JI
Xnarsul
Mex(AYHilpoAI{oe
lraHI}IeHOBArrHe
flKTr.rBHbrx
Berrlecrn:
potassiurl
chloricle
2"
KonuqesrBe*Hurfi
H Kaqecr*er{Hbrfi
cocran.
Kalnn
xfiopuAa
- 4 , 0 r
(Eur.
Ph.,
monograph
0l
g5)
BoAr,l
,{nrr
HnT'exuprfi
-
go
100
nrn
(Eur.
ph.,
rnonograph
0169)
3. sapnraue'Trqec*arr
sopnra:
pacrBop
A,,rx
nucfryrnfi
4
%.
4.
KnllgurrccrcHe
xapaKTepucrr{Kn
4.1,
floma3aHltrr
llpodllrnaKTI4Ka
w
rerleH,e
rHnoKaJIHer\,rr{H,
n':Bauuolyr
pa3Jrr.rqFrbrMH
npprr{HHaN{pr
(npuertt
ca^ryperl4KoB'
noBbIIIIeHHoe
BbIAerreHHe
Karurr
noqKaMpr
vt
r.,r.);
npo{:unaKTl'tKil
rHnoKaJIHEivI:HH
y
6onrHux
c
apurncreii
cepnua
vfrw
6orurux,
npl,fHl{Malorqnx
npe[apaTbr
HaIIepsTflFrKHl
HHTOKC[rKar{Hfl
npeflapaTal,rH
Hanepc.TrHKH.
4.2.
Pexr{rvt
Ao3r{poBarrun
Irpenapsr,
ttct
.oJtbgosflm.b
mofi
bto
o
pasfugsJre*How
eude.
Brpocnuiu,
rlerf,h{
I{ no}KHTIhIM
BHyrpprBeHHO
KareJrLr{o
(20
-
30
Kan.
r
uun.)
Ao
I
,5
r
s
500
Mrl
H3oroHpIr{ecKoro
pacrnopa
r{aTpr.rfl
xnop}rra
uns
5
oh
pacrnopa
rnror(o3br.
{o:a
ilpenapara
3aBr.rcHT
oT
rroxa3aTeJrfl
coAep]Kanr.rlt
r(aJr}{,
B
cbrBoporKe
KpoBr{.
[e
dr
H'{HT
K
a"yrr{Jr
p
aacq
r{TbrB
a}or
no
$
oprnryre
:
Itarlui
(rrrnro.ur)
*
Bes
rera (xr)
x
0,2
x
Z
x 4,5
I
ul
npsnapara
coAepxuT
0,52
Mruorrb
r{aJrpr.fl.
4,5
-
Hopri{B.rrbur,rrl
ypoBeHb
Ka.ilr.{fl
B
crbrBoporxg
('s
N{Nrorb},
Marccunrturrlr-raJr
cyT'orlHag
Aora
He
Ao,[xna
rrpeBlrrularb
Te"rIa.
llpn
geo6xo,xprr\,tocTl.r
Hcrrorrb3o*aH,n
Bbrco*I4x
.,{.g
r.J
AOJI)I.CFI
IsBOAI,ITI}C'I
C
NOMOIIIbIO
INH$Y:rrOHHOfO
HACOCA.
4.3.
flporuBoro
Ka3aHHfl
frnnepraJr,eJvrr.{fl,
r'nepxJropeMprfl,
Hapy[ueHHe
anypneri.
a3oT'einuel:r),
6oterHn
AAflucoHa"
cy/Iopofpr.
4.4.
Oco6ue
yKa3aI{Hff
Kon4eun'puposfiH*btl-(
pilcrnsop!
Irpu+teil*mt]
pttsfuuen€H*bt.,t
s pucm.ape
Harnpun
.unopuda
QrF
%
unu
S
yo
znwKosw.
llpenapar:
neo6'\orl{i\'ro
ITpHN{eH-srb
Br{yTpr,rrJsr-rFro
c
ocropox(Hocrbm
pf3-3a
pl'rc*a
pa:l'r.r'fr.r
fr.Inep*aflHeM'.rfi.